[go: up one dir, main page]

AR039690A1 - Difenilazetidinonas sustituidas por grupos acidos, medicamentos que comprenden estos compuestos y su uso - Google Patents

Difenilazetidinonas sustituidas por grupos acidos, medicamentos que comprenden estos compuestos y su uso

Info

Publication number
AR039690A1
AR039690A1 ARP030102144A ARP030102144A AR039690A1 AR 039690 A1 AR039690 A1 AR 039690A1 AR P030102144 A ARP030102144 A AR P030102144A AR P030102144 A ARP030102144 A AR P030102144A AR 039690 A1 AR039690 A1 AR 039690A1
Authority
AR
Argentina
Prior art keywords
alkyl
phenyl
cooh
replaced
alkylene
Prior art date
Application number
ARP030102144A
Other languages
English (en)
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of AR039690A1 publication Critical patent/AR039690A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/568Four-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Los compuestos son convenientes para usar como hipolipidémicos. Reivindicación 1: Un compuesto de la fórmula (1), en la que: R1, R2, R3, R4, R5, R6 independientemente uno de otro son alquileno (C0-30)-(LAG)n, donde n = 1-5 y donde uno o más átomos de carbono del radical alquileno están reemplazados por -S(O)n-, donde n = 0-2, -O-, -C(=O)-, -(C=S)-, -CH=CH-, -CsC-, -N-(alquilo (C1-6))-, -N(fenilo), -N(alquilo (C1-6)fenilo)-, -N(CO-(CH2)1-10-COOH)- o -NH-; H, F, Cl, Br, I, CF3, NO2, N3, CN, COOH, COO-alquilo (C1-6), CONH2, CONH-alquilo (C1-6), CON[alquilo (C1-6)]2, alquilo (C1-6), alquenilo (C2-6), alquinilo (C2-6), O-alquilo (C1-6), donde uno, más o todos los hidrógenos en los radicales alquilo pueden estar reemplazados por flúor C(=NH)(NH2), PO3H2, SO3H; SO2-NH2, SO2NH-alquilo (C1-6), SO2N[alquilo (C1-6)]2, S-alquilo (C1-6), S-(CH2)n-fenilo, SO-alquilo (C1-6), SO-(CH2)n-fenilo, -SO2-alquilo (C1-6), SO2-(CH2)n-fenilo, donde n = 0-6 y el radical fenilo puede estar sustituido hasta dos veces con F, Cl, Br, OH, CF3, NO2, CN, OCF3, O-alquilo (C1-6), alquilo (C1-6), NH2; NH2, NH-alquilo (C1-6), N(alquilo (C1-6))2, NH-acilo (C1-7), fenilo, O-(CH2)n-fenilo, donde n = 0-6, donde el anillo fenilo puede estar mono o trisustituido con F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, O-alquilo (C1-6), alquilo (C1-6), NH2, NH-alquilo (C1-6), N(alquilo (C1-6))2, SO2-CH3, COOH, COO-alquilo (C1-6), CONH2; (LAG)n es -(CH2)0-10-SO3H, -(CH2)0-10-O-P(O)(OH)2, -(CH2)0-10-O-P(O)(OH)2, -(CH2)0-10-COOH; y n puede ser 1-5, donde en cada caso al menos uno de los radicales R1 a R6 pueden tener el significado alquileno (C1-30)-(LAG)n, donde n = 1-5 y uno o más átomos de carbono del radical alquileno están reemplazados por -S(O)n-, donde n = 0-2, -O-, -(C=O)-, -(C=S)-, -CH=CH-, -CsC-, -N(alquilo (C1-6))-, -N(fenilo)-, N-(alquilo (C1-6)fenilo)-, -N(CO-(CH2)1-10-COOH)- o -NH-; y sus sales aceptables farmacéuticamente, excepto para el compuesto ácido 2-{[4-(4-{1-(4-fluorofenil)-3-[3-(fluorofenil)-3-hidroxipropil]-4-oxoaze-tidin-2-il}fenoxi)butil]metilamino}etanosulfónico y aquellos compuestos en los que los radicales R1-6 tienen el significado -O-(CH2)1-10-COOH, COOH-alquileno-(C1-6) o -COOH.
ARP030102144A 2002-06-19 2003-06-17 Difenilazetidinonas sustituidas por grupos acidos, medicamentos que comprenden estos compuestos y su uso AR039690A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10227508A DE10227508A1 (de) 2002-06-19 2002-06-19 Säuregruppen-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung

Publications (1)

Publication Number Publication Date
AR039690A1 true AR039690A1 (es) 2005-03-09

Family

ID=29719283

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030102144A AR039690A1 (es) 2002-06-19 2003-06-17 Difenilazetidinonas sustituidas por grupos acidos, medicamentos que comprenden estos compuestos y su uso

Country Status (28)

Country Link
EP (1) EP1517891B1 (es)
JP (1) JP2005533073A (es)
KR (1) KR20050008835A (es)
CN (1) CN100467448C (es)
AR (1) AR039690A1 (es)
AU (1) AU2003238210B2 (es)
BR (1) BR0311896A (es)
CA (1) CA2490112A1 (es)
DE (1) DE10227508A1 (es)
EC (1) ECSP045497A (es)
HN (1) HN2003000185A (es)
HR (1) HRPK20041201B3 (es)
IL (1) IL165789A0 (es)
MA (1) MA27206A1 (es)
MX (1) MXPA04012093A (es)
NO (1) NO20050134L (es)
OA (1) OA12869A (es)
PA (1) PA8576101A1 (es)
PE (1) PE20040564A1 (es)
PL (1) PL372700A1 (es)
RS (1) RS108404A (es)
RU (1) RU2287522C2 (es)
SV (1) SV2004001548A (es)
TN (1) TNSN04250A1 (es)
TW (1) TW200413311A (es)
UA (1) UA78577C2 (es)
UY (1) UY27853A1 (es)
WO (1) WO2004000805A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
WO2005061452A1 (en) 2003-12-23 2005-07-07 Astrazeneca Ab Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity
CA2589483C (en) 2004-12-03 2013-10-29 Schering Corporation Substituted piperazines as cb1 antagonists
BRPI0609614A2 (pt) * 2005-04-04 2010-04-20 Univ Pontificia Catolica Chile uso de ezetimiba na prevenção e tratamento de litìases de colesterol na árvore biliar
EP1902046B1 (en) 2005-06-20 2009-12-02 Schering Corporation Piperidine derivatives useful as histamine h3 antagonists
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
AR060623A1 (es) 2006-04-27 2008-07-02 Astrazeneca Ab Compuestos derivados de 2-azetidinona y un metodo de preparacion
NZ611323A (en) * 2006-06-23 2014-10-31 Abbvie Bahamas Ltd Cyclopropyl amine derivatives as histamin h3 receptor modulators
JP2010500300A (ja) 2006-08-08 2010-01-07 サノフィ−アベンティス アリールアミノアリール−アルキル−置換イミダゾリジン−2,4−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
DE102007002260A1 (de) 2007-01-16 2008-07-31 Sanofi-Aventis Verwendung von substituierten Pyranonsäurederivaten zur Herstellung von Medikamenten zur Behandlung des Metabolischen Syndroms
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CN101200443B (zh) * 2007-10-17 2011-06-29 中国药科大学 氮杂环丁酮衍生物、其制备方法及含有它们的药物组合
DE102007063671A1 (de) 2007-11-13 2009-06-25 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
CA2754384A1 (en) 2009-03-06 2010-09-10 Lipideon Biotechnology Ag Pharmaceutical hypocholesterolemic compositions
CN101993403B (zh) 2009-08-11 2012-07-11 浙江海正药业股份有限公司 氮杂环丁酮类化合物及医药应用
KR20120060207A (ko) 2009-08-26 2012-06-11 사노피 신규한 결정성 헤테로방향족 플루오로글리코시드 수화물, 이들 화합물을 포함하는 약제 및 이들의 용도
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3300B (en) * 1992-12-23 1995-06-26 Schering Corp Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5756470A (en) * 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
RU2181297C2 (ru) * 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
DE10042447A1 (de) * 2000-08-29 2002-03-28 Aventis Pharma Gmbh Protein aus dem Darm von Wirbeltieren, welches Cholesterin absorbiert, sowie Verwendung dieses Proteins zur Identifizierung von Inhibitoren des intestinalen Cholesterintransports
IL156552A0 (en) * 2000-12-21 2004-01-04 Aventis Pharma Gmbh Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
IL156548A0 (en) * 2000-12-21 2004-01-04 Aventis Pharma Gmbh Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
DE50111751D1 (de) * 2000-12-21 2007-02-08 Sanofi Aventis Deutschland Neue diphenzylazetidinone, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung zur behandlung von lipidstoffwechselstörungen

Also Published As

Publication number Publication date
UA78577C2 (en) 2007-04-10
PL372700A1 (en) 2005-07-25
AU2003238210A1 (en) 2004-01-06
HRP20041201A2 (en) 2005-08-31
WO2004000805A1 (de) 2003-12-31
NO20050134D0 (no) 2005-01-11
RU2005101093A (ru) 2005-07-20
HRPK20041201B3 (en) 2006-12-31
CN1662495A (zh) 2005-08-31
EP1517891A1 (de) 2005-03-30
NO20050134L (no) 2005-03-18
JP2005533073A (ja) 2005-11-04
DE10227508A1 (de) 2004-01-08
HN2003000185A (es) 2005-10-20
RS108404A (sr) 2007-02-05
AU2003238210B2 (en) 2008-10-23
SV2004001548A (es) 2004-03-19
PA8576101A1 (es) 2004-02-07
PE20040564A1 (es) 2004-10-25
OA12869A (en) 2006-09-15
CA2490112A1 (en) 2003-12-31
MXPA04012093A (es) 2005-04-19
CN100467448C (zh) 2009-03-11
KR20050008835A (ko) 2005-01-21
IL165789A0 (en) 2006-01-15
UY27853A1 (es) 2003-12-31
TNSN04250A1 (en) 2007-03-12
TW200413311A (en) 2004-08-01
HK1079511A1 (zh) 2006-04-07
ECSP045497A (es) 2005-03-10
EP1517891B1 (de) 2013-04-03
MA27206A1 (fr) 2005-01-03
RU2287522C2 (ru) 2006-11-20
BR0311896A (pt) 2005-04-05

Similar Documents

Publication Publication Date Title
AR039690A1 (es) Difenilazetidinonas sustituidas por grupos acidos, medicamentos que comprenden estos compuestos y su uso
AR039689A1 (es) Difenilazetidinonas sustituidas, medicamentos que comprenden estos compuestos y su uso
AR034282A1 (es) Derivados de difenilazetidinona, medicamentos que contienen estos compuestos, procedimiento para su preparacion, y su utilizacion para la preparacion de medicamentos
AR033600A1 (es) Difenilazetidinona, medicamentos que contienen estos compuestos, procedimiento para su preparacion, y su utilizacion para preparar medicamentos
DK2316831T3 (da) 2-(Morpholin-4-yl)pyrimidiner som phosphotidylinositol (PI)-3-kinaseinhibitorer samt deres anvendelse ved behandling af cancer
DK1585739T3 (da) Substituerede arylcyclopropylacetamider som glucokinaseaktivatorer
AR002746A1 (es) Compuestos derivados de pirimidina condensados con un anillo heterociclico y composicion farmaceutica conteniendo dichos compuestos.
AR040474A1 (es) Derivados de tiofenolglicosido, procedimientos para la preparacion de los mismos, medicamentos que contienen estos compuestos, y el uso de los mismos
PL1996180T3 (pl) Pochodne benzamidu i pirydyloamidu jako czynniki antybakteryjne
IS7857A (is) Setnar pýrróló-pýrasól afleiður sem kínasa hindrar
PE20081530A1 (es) Nuevos compuestos 617
DK1767535T3 (da) Syntese af epothiloner, mellemprodukter deraf, analoge og deres anvendelse
CY1109510T1 (el) Επιλεγμενοι ανταγωνιστες toy cgrp, μεθοδος για την παραγωγη τους και για τη χρηση τους ως φαρμακων
CY1113450T1 (el) Διαμινοπυριμιδινες ως ρ2χ3 και ρ2χ2/3 ανταγωνιστες
ATE302775T1 (de) Carbolinderivate
CY1107853T1 (el) Χρησεις αντισπασμωδικων αμινοξεων για τη θεραπευτικη αγωγη διπολικων διαταραχων
ECSP045483A (es) Derivados de heteroarilamida benzocondensada de tienopiridinas útiles como agentes terapéuticos, composiciones farmacéuticas que incluyen a los mismos, y métodos para su uso
ID29452A (id) 4-okso-1,4-dihidro-3-quinolinkarboksamida sebagai agen-agen antivirus
ATE433981T1 (de) Heterocyclische verbindungen
ATE477256T1 (de) Thienylverbindungen
CA2655527C (en) Cinnamoyl-piperazine derivatives and their use as par-1 antagonists
ATE346067T1 (de) Carbolinderivate
ATE387452T1 (de) Spiroverbindungen mit npy antagonistischer wirkung
ATE442362T1 (de) Pyridylcyanoguanidin verbindungen
AR042341A1 (es) Derivados de arilen-(2-amino-fenil)-carboxamida, su elaboracion y su uso como agentes farmaceuticos

Legal Events

Date Code Title Description
FB Suspension of granting procedure